Tango Therapeutics, Inc. (TNGX) Return on equity 2020–2025
Tango Therapeutics, Inc. (TNGX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-29.3%FY2025 · since FY2020: -134.6% → -29.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -29.3% | +36.0 pp |
| FY2024 | -65.3% | -25.1 pp |
| FY2023 | -40.2% | +3.2 pp |
| FY2022 | -43.4% | -26.5 pp |
| FY2021 | -16.9% | +117.8 pp |
| FY2020 | -134.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TNGX financial trends
TNGX RevenueTNGX Net incomeTNGX Net marginTNGX Gross profitTNGX Gross marginTNGX Operating incomeTNGX Operating marginTNGX Operating cash flowTNGX Free cash flowTNGX Capital expendituresTNGX Stock buybacksTNGX Dividends paidTNGX Total assetsTNGX Total liabilitiesTNGX Shareholders’ equityTNGX overview →